ClinicalTrials.gg
CompletedNCT05306418Updated Nov 13, 2025

A Research Study Looking at Mim8 in Children With Haemophilia A With or Without Inhibitors

A Phase 3 interventional study of Mim8 in Haemophilia A With or Without Inhibitors, sponsored by Novo Nordisk A/S. Completed at 52 sites in 19 countries. Open to participants aged 1 Year to 11 Years. Per ClinicalTrials.gov, last updated 2025-11-13.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2024, 2 years ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Nov 2025.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
70
Allocation
Not applicable
Ages
1 Year to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 92 studies in Hemophilia A by Novo Nordisk A/S — 8 open to participants now, 12 under way, 5 of them phase 3. Hemophilia A · Novo Nordisk A/S.

Enrollment
17th of 59
70 · median 38
Started
2022
with 2 others
Phase 3
21 of 92
1 open now
Registered
79th of 92
by date

Among the 92 studies in Hemophilia A by Novo Nordisk A/S, this one is the 17th largest by enrollment of the 59 interventional ones that give a count, is one of 3 that started in 2022, is one of 21 in phase 3, and was the 79th registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

8 of the 92 studies in Hemophilia A by Novo Nordisk A/S are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Who these studies take

Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.

This study: 1 Year to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 92 studies in Hemophilia A by Novo Nordisk A/S, or all of them as a file.
02

Study summary

This study is looking at how Mim8 works compared to other medicines in children with haemophilia A, who either have inhibitors or do not have inhibitors.

Mim8 is a new medicine that will be used for prevention of bleeds. Mim8 will be injected with a thin needle into the skin. The study will last for about 54-98 weeks, from screening to follow-up visit, In case the participant experiences bleeds, these can be treated with additional haemostatic medicine as agreed with the study doctor.

03

Conditions studied

  • Haemophilia A With or Without Inhibitors

Browse trials for

04

Who can participate

Ages eligible
1 Year to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.
  2. Male and female participants with the diagnosis of congenital haemophilia A of any severity based on medical records.
  3. Aged 1-11 years (both inclusive) at the time of signing informed consent.
  4. For previously treated participants :

    1. Participant has been prescribed treatment with FVIII concentrate or bypassing agent in the last 26 weeks prior to screening.
    2. Participants with endogenous FVIII activity greater than or equal to 1%, based on medical records, must have at least 1 treated bleed during the previous 26 weeks before screening for which factor VIII concentrate or bypassing agent has been prescribed (no requirements for participants with FVIII activity below 1%).
  5. For previously untreated participants:

    a. Diagnosis of severe haemophilia A (endogenous FVIII activity below 1%) based on medical records.

  6. Child and parent/caregiver willingness and ability to comply with scheduled visits and study procedures, including the completion of diary and patient-reported outcomes questionnaires.( For China mainland; assessed at the investigator's discretion unless otherwise stated.)

Exclusion criteria

Exclusion criteria:

  1. Known or suspected to trial product or related products.(For China mainland; assessed at the investigator's discretion unless otherwise stated.)
  2. Previous participation in this study. Participation is defined as signed .
  3. Participation (i.e., signed informed consent) in any interventional clinical study with receipt of last dose within 6 months (or 5 half-lives of the medicinal product, whichever is shorter) before planned randomisation.
  4. Exposure to non-factor haemostatic products for bleeding prophylaxis within 6 months (or 5 half-lives of the medicinal product, whichever is shorter) before planned randomisation, for participants not included in the run-in.
  5. Known congenital or acquired coagulation disorders other than haemophilia A.
  6. Other conditions (e.g. disease) or laboratory abnormality that may increase risk of bleeding or thrombosis, as evaluated by the investigator.(For China mainland; assessed at the investigator's discretion unless otherwise stated.)
  7. Any disorder, except for conditions associated with haemophilia A, that in the investigator's opinion might jeopardise the participant's safety or compliance with the protocol.(For China mainland; assessed at the investigator's discretion unless otherwise stated.)
  8. Mental incapacity, unwillingness to cooperate or a language barrier precluding adequate understanding and cooperation.(For China mainland; assessed at the investigator's discretion unless otherwise stated.)
  9. Lack of adequate parental/caregiver support to enter accurately and timely information regarding treatment and bleeding episodes into an (electronic) diary.(For China mainland; assessed at the investigator's discretion unless otherwise stated.)
  10. Previous or current treatment for thromboembolic disease (with the exception of previous catheter-associated thrombosis for which anti-thrombotic treatment is not currently ongoing) or signs of thromboembolic disease.
  11. Major surgery planned to take place after screening.(For China mainland; assessed at the investigator's discretion unless otherwise stated.)
  12. Immune tolerance induction planned to take place after treatment initiation.(For China mainland; assessed at the investigator's discretion unless otherwise stated.)
  13. Hepatic dysfunction defined as (AST) and/or alanine aminotransferase (ALT) greater than 3 times the combined with total greater than 1.5 times the upper limit of normal measured at screening.
  14. Serum creatinine above 1.5 x upper limit of normal (ULN), measured at screening.
  15. Pregnancy (female participants).(Will be assessed at investigator's discretion, according to suspicion of pregnancy.)
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    Mim8

    52-week treatment period with a part 1 and part 2, where all participants receive Mim8 prophylaxis

    Drug: Mim8

Interventions

  • DrugMim8

    For treatment part 1, all participants will start on once-weekly treatment and continue on this regimen until week 26. For treatment part 2, starting at week 26, all participants will be offered the choice to remain on once-weekly or switch to once-monthly dosing. Mim8 will be injected with a thin needle into the skin

06

What researchers measure

Primary outcomes

  1. Number of treatment emergent adverse events

    Count of events

    Time frame: From treatment initiation to follow up visit (week 0 to week 72)

Secondary outcomes

  1. Number of treated bleeds

    Count of bleeds

    Time frame: From treatment initiation to end of treatment (week 0 to week 52)

  2. Number of treated spontaneous bleeds

    Count of bleeds

    Time frame: From treatment initiation to end of treatment (week 0 to week 52)

  3. Number of treated traumatic bleeds

    Count of bleeds

    Time frame: From treatment initiation to end of treatment (week 0 to week 52)

  4. Number of treated joint bleeds

    Count of bleeds

    Time frame: From treatment initiation to end of treatment (week 0 to week 52)

  5. Number of treated target joint bleeds

    Count of bleeds

    Time frame: From treatment initiation to end of treatment (week 0 to week 52)

  6. Number of injection site reactions

    Count of reactions

    Time frame: From treatment initiation to end of treatment (week 0 to week 52)

  7. Consumption of factor product per bleed treatment (number of injections)

    Count of injections

    Time frame: From run-in initiation to end of treatment (week -26 to week 52)

  8. Occurrence of anti-Mim8 antibodies

    Count of participants

    Time frame: From treatment initiation to end of treatment (week 0 to week 52)

  9. Mim8 plasma concentration

    µg/mL

    Time frame: From treatment initiation to end of treatment (week 0 to week 52)

  10. Change in physical function domain of PEDS QL (Paediatric Quality of Life inventory) Generic Core Scales

    Score on a scale 0-100 (applies for scale scores and total score). A higher score indicates a better health-related quality of life

    Time frame: From treatment initiation to end of treatment (week 0 to week 52)

  11. Treatment preference for Mim8 versus previous treatment using Caregiver H PPQ (Caregiver Haemophilia Patient Preference )

    Percentage of participants

    Time frame: Once during treatment (week 26)

  12. Change in participants' treatment burden using the Hemo TEM (Haemophilia treatment experience measure)

    Score on a scale 0-100 (applies for scale scores and total score). A lower score indicates a lower treatment burden.

    Time frame: From treatment initiation to end of treatment (week 0 to week 52)

07

Study locations

52 sites
  • Children's Hospital Los Angeles - Endocrinology
    Los Angeles, California 90027, United States
  • Univ of Colorado Sch of Med
    Aurora, Colorado 80045, United States
  • St Joseph's Hospital Foundation
    Tampa, Florida 33607, United States
  • Children's Healthcare Atlanta
    Atlanta, Georgia 30322, United States
  • Children's Hospital at Memorial Health
    Savannah, Georgia 31404, United States
  • University of Iowa_Iowa City
    Iowa City, Iowa 52242, United States
  • Univ Hosp Cleveland Med Ctr
    Cleveland, Ohio 44106, United States
  • Penn State MS Hershey Med Ctr
    Hershey, Pennsylvania 17033-2360, United States
  • St Christopher Hosp for Child
    Philadelphia, Pennsylvania 19134, United States
  • McMaster Children's Hospital
    Hamilton, Ontario L8N 3Z5, Canada
  • The Hospital for Sick Children
    Toronto, Ontario M5G 1X8, Canada
  • Beijing Children's Hospital, Capital Medical University
    Beijing, Beijing Municipality 100045, China
  • Beijing Children's Hospital,Capital Medical University
    Beijing, Beijing Municipality 100045, China
  • Nanfang Hospital, Southern Medical University-Haematology
    Guangzhou, Guangdong 510515, China
  • Chengdu Women's and Children's Central Hospital
    Chengdu, Sichuan 610000, China
  • Institute of Hematology and Blood Diseases Hospital, Tianjin-Hematology
    Tianjin, Tianjin Municipality 300020, China
  • Children's Hospital, Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310052, China
  • Universitätsklinikum Bonn - Institut für Experimentelle Hämatologie
    Bonn, 53127, Germany
  • Nirmal Hospital Pvt. Ltd.
    Surat, Gujarat 395002, India
  • Seth GS Medical College & KEM Hospital
    Mumbai, Maharashtra 400012, India
  • Sahyadri Super Speciality Hospital
    Pune, Maharashtra 411004, India
  • J K Lon Hospital
    Jaipur, Rajasthan 302004, India
  • Post Graduate Institute of Child Health
    Noida, Uttar Pradesh 201303, India
  • Sheba MC - The Israeli National Hemophilia Center
    Tel Litwinsky, 52621, Israel
  • Ospedale Pediatrico Bambino Ges
    Rome, 00165, Italy
  • A.O.U. Città della Salute e della Scienza di Torino-Ospedale
    Torino, 10126, Italy
  • Ota Memorial Hospital_Pediatrics
    Gunma, 373-8585, Japan
  • Sapporo Tokushukai Hospital_Pediatrics
    Hokkaido, 004-0041, Japan
  • Saitama Children's Med Centre_Hematology-Oncology
    Saitama, 330-8777, Japan
  • Ogikubo Hospital_Pediatries & Blood
    Tokyo, 167-0035, Japan
  • Children Oncohaematology department Children's Hospital,
    Vilnius, 08406, Lithuania
  • Academisch Medisch Centrum
    Amsterdam, 1105 AZ, Netherlands
  • UMC Utrecht, Van Creveldkliniek
    Utrecht, 3584 CX, Netherlands
  • Uniwersytecki Szpital Kliniczny im. J.Mikulicza-Radeckiego
    Wroclaw, Lower Silesian Voivodeship 50-556, Poland
  • CSK UM Uniwersyteckie Centrum Pediatrii im. M. Konopnickiej
    Lodz, 91-738, Poland
  • Uniwersytecki Szpital Dzieciecy, Dzial Krwiolecznictwa
    Lublin, 20-093, Poland
  • Unidade Local de Saúde São José EPE- Hospital D. Estefânia
    Lisbon, 1169-045, Portugal
  • ULS São João, E.P.E.
    Porto, 4200-319, Portugal
  • SAHI Kuzbass Hospital(former Regional clinical hospital)
    Kemerovo, 650066, Russia
  • Children Regional Clinical Hospital
    Krasnodar, 350007, Russia
  • Morozovskaya municipal children hospital
    Moscow, 119049, Russia
  • Republican Hospital n.a. V. A. Baranov
    Petrozavodsk, 185019, Russia
  • Charlotte Maxeke Johannesburg Academic Hospital
    Parktown, Johannesburg, Gauteng 2193, South Africa
  • Daejeon Eulji Medical Center, Eulji University
    Daejeon, 35233, South Korea
  • Severance Hospital, Yonsei University Health System
    Seoul, 03722, South Korea
  • Hospital Sant Joan de Déu
    Esplugues Llobregat, 08950, Spain
  • Hospital Universitario La Paz
    Madrid, 28046, Spain
  • Universitätsklinik für Kinderheilkunde
    Bern, 3010, Switzerland
  • Pädiatrische Onkologie-Hämatologie
    Lucerne, 6000, Switzerland
  • National Taiwan University Children's Hospital
    Taipei, 100, Taiwan
  • Arthur Bloom Haemophilia Centre
    Cardiff, CF14 4XW, United Kingdom
  • St Thomas' Hospital - Haemostasis and Thrombosis Centre
    London, SE1 7EH, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2022 to primary completion in Nov 2024, 31 months.

Of 89 industry-sponsored phase 3 interventional studies under Hemophilia A, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 56. This study's 31 months is close to that.

Counting every sponsor, half of 91 studies reached it within 33 months; a quarter within 20 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2022
First posted
Apr 1, 2022
StartActual
Apr 4, 2022
Primary completionActual
Nov 13, 2024
CompletionActual
Nov 13, 2024
Results delay requested
Nov 11, 2025
Last update
Nov 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05306418
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Apr 1, 2022
Start date
Apr 4, 2022
Primary completion
Nov 13, 2024
Completion
Nov 13, 2024
Last update
Nov 13, 2025

Study contacts

Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denecimig

Start the discussion